Day One Biopharmaceuticals (DAWN) Earnings
Price: $7.19
Market Cap: $728.74M
Market Cap: $728.74M
Revenue (TTM): $131.16M
Net Income: $-95.50M
Net Income: $-95.50M
P/E Ratio: -7.05
EPS (TTM): $-1.02
EPS (TTM): $-1.02
Earnings Dates
Day One Biopharmaceuticals (DAWN) reports its earnings quarterly. Here are the key details:
Next Earnings Date
- Date: May 05, 2025
- Time of Day: Before Market Open
- Estimated EPS: $-0.45
Last Earnings Report
- Date: February 25, 2025
- EPS: $-0.69
- EPS Estimate: $-0.35
Day One Biopharmaceuticals's next earnings report is scheduled for May 05, 2025.
In its last earnings report on February 25, 2025, Day One Biopharmaceuticals reported earnings per share (EPS) of $-0.69, compared to an estimated EPS of $-0.35. The company reported revenue of $29.21M, compared to an estimated revenue of $27.83M.
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-26 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $-0.41 | $0.38 |
Earnings History
| Date | EPS | EPS Estimate | Revenue | Revenue Estimate |
|---|---|---|---|---|
| February 25, 2025 | $-0.69 | $-0.35 | $29.21M | $27.83M |
| October 30, 2024 | $0.38 | $-0.41 | $93.76M | $28.48M |
| July 30, 2024 | $-0.05 | $-0.67 | $8.19M | $1.03M |
| May 06, 2024 | $-0.72 | $-0.67 | $- | $- |
| February 26, 2024 | $-0.64 | $-0.57 | $560.00K | $- |
| November 06, 2023 | $-0.54 | $-0.60 | $- | $- |
| August 07, 2023 | $-0.61 | $-0.60 | $- | $- |
| May 01, 2023 | $-0.59 | $-0.60 | $- | $- |
| March 06, 2023 | $-0.56 | $-0.57 | $- | $- |
| November 07, 2022 | $-0.53 | $-0.53 | $- | $- |
| August 04, 2022 | $-0.60 | $-0.49 | $- | $- |
| May 12, 2022 | $-0.48 | $-0.39 | $- | $- |
| March 07, 2022 | $-0.36 | $-0.36 | $- | $- |
| November 08, 2021 | $-0.33 | $-0.28 | $- | $- |
| August 10, 2021 | $-5.04 | $-0.31 | $- | $- |
| May 27, 2021 | $-0.56 | $ | $- | $- |
| March 30, 2021 | $-0.25 | $ | $- | $- |
| September 29, 2020 | $-0.05 | $ | $- | $- |
| June 29, 2020 | $-0.03 | $ | $- | $- |
Annual Earnings
Annual Revenue
$131.16M
Fiscal Year 2024Annual Net Income
$-95.50M
Fiscal Year 2024Annual EPS
$-1.02
Fiscal Year 2024Quarterly Earnings
Revenue
$29.21M
Quarter Ending December 31, 2024Net Income
$-65.71M
Quarter Ending December 31, 2024EPS
$-0.70
Quarter Ending December 31, 2024Earnings Metrics
Earnings Yield
-8.05%
Year Ending December 31, 2024P/E Ratio
-12.42
Year Ending December 31, 2024Revenue Per Share
$1.40
Year Ending December 31, 2024Earnings Yield (TTM)
-14.19%
Trailing Twelve MonthsP/E Ratio (TTM)
-7.05
Trailing Twelve MonthsRevenue Per Share (TTM)
$1.40
Trailing Twelve MonthsFrequently Asked Questions
Day One Biopharmaceuticals's next earnings date is scheduled for May 05, 2025. The earnings call is expected to take place before market open.
In its last earnings report on February 25, 2025, Day One Biopharmaceuticals reported earnings per share (EPS) of $-0.69, compared to an estimated EPS of $-0.35. The company reported revenue of $29.21M, compared to an estimated revenue of $27.83M.
Day One Biopharmaceuticals's current Price-to-Earnings (P/E) ratio is -12.42. The trailing twelve months (TTM) P/E ratio is -7.05. The P/E ratio is a valuation metric that compares a company's current share price to its earnings per share (EPS). A higher P/E ratio suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E ratio.
For the fiscal year ending December 31, 2024, Day One Biopharmaceuticals reported total revenue of $131.16M and net income of $-95.50M. This represents a net profit margin of -0.7280822806.
Day One Biopharmaceuticals's earnings yield is -8.05%. The earnings yield is the inverse of the P/E ratio and represents the percentage of each dollar invested in the stock that was earned by the company.
Day One Biopharmaceuticals's return on equity (ROE) is -18.99%. ROE is a measure of financial performance calculated by dividing net income by shareholders' equity. It measures how effectively management is using a company's assets to create profits.
Day One Biopharmaceuticals's gross profit margin is 95.98%. This indicates that for every dollar of revenue, the company retains $0.96 as gross profit after accounting for the cost of goods sold.